Read by QxMD icon Read


R Thuret, S Hurel, F Kleinclauss, M O Timsit
OBJECTIVES: To describe lower urinary tract symptoms (LUTS) and their management in renal transplant candidates and recipients. MATERIAL AND METHODS: Relevant publications were identified through Medline ( and Embase ( database using the following keywords, alone or in association: "transplantation", "prostate hyperplasia", "transurethral resection of prostate", "urinary incontinence", "LUTS", "pelvic floor dysfunction"...
October 7, 2016: Progrès en Urologie
Mary-Ellen Taplin, Rana R McKay, Lillian Werner, Elahe A Mostaghel, Rosina T Lis, Olga Voznesensky, Zhenwei Zhang, Brett Marck, Alvin M Matsumoto, Liran Domachevsky, Katherine A Zukotynski, Manoj K Bhasin, Glenn J Bubley, Bruce Montgomery, Philip W Kantoff, Steven P Balk
PURPOSE: Despite the efficacy of abiraterone, a CYP17A1 inhibitor, in metastatic castration-resistant prostate cancer (CRPC), nearly all patients develop resistance. The purpose of this phase II study was to evaluate mechanisms of resistance to more complete androgen synthesis inhibition with abiraterone and dutasteride. EXPERIMENTAL DESIGN: Eligible metastatic CRPC patients underwent a baseline metastasis biopsy. Patients received abiraterone and prednisone for two 4-week cycles...
September 28, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Jason M Hirshburg, Petra A Kelsey, Chelsea A Therrien, A Carlo Gavino, Jason S Reichenberg
Finasteride and dutasteride, both 5-alpha reductase inhibitors, are considered first-line treatment for androgenetic hair loss in men and used increasingly in women. In each case, patients are expected to take the medications indefinitely despite the lack of research regarding long-term adverse effects. Concerns regarding the adverse effects of these medications has led the United States National Institutes of Health to add a link for post-finasteride syndrome to its Genetic and Rare Disease Information Center...
July 2016: Journal of Clinical and Aesthetic Dermatology
Maral DerSarkissian, Yongling Xiao, Mei Sheng Duh, Patrick Lefebvre, Andrine R Swensen, Christopher F Bell
BACKGROUND: Benign prostatic hyperplasia (BPH) is a common disease in men that is characterized by lower urinary tract symptoms. Pharmacologic treatment with alpha blockers (ABs) and 5-alpha reductase inhibitors (5ARIs) is recommended to alleviate symptoms, prevent disease progression that can lead to complications, and reduce health care costs. OBJECTIVE: To compare clinical, economic, and health care resource utilization outcomes among BPH patients treated with early continuous combination AB and 5ARI therapy (dutasteride vs...
October 2016: Journal of Managed Care & Specialty Pharmacy
Katrina Wilcox Hagberg, Hozefa A Divan, Rebecca Persson, J Curtis Nickel, Susan S Jick
OBJECTIVE:  To estimate the risk of erectile dysfunction in men who used 5-α reductase inhibitors to treat benign prostatic hyperplasia or alopecia. DESIGN:  Cohort studies with nested case-control analyses. SETTING:  UK Clinical Practice Research Datalink. POPULATION:  Two populations of men free of risk factors for erectile dysfunction and other sexual dysfunction or its treatment: men aged 40 or more with benign prostatic hyperplasia who received a prescription for a 5-α reductase inhibitor (finasteride or dutasteride) or α blocker, or both, and men aged 18-59 with alopecia...
2016: BMJ: British Medical Journal
Daimantas Milonas, Stasys Auskalnis, Giedrius Skulcius, Inga Gudinaviciene, Mindaugas Jievaltas, Steven Joniau
PURPOSE: High-grade prostatic intraepithelial neoplasia (HGPIN) is a potential precursor of prostate cancer (PCa), and patients with HGPIN are at high risk for PCa development. Objective of our study was to evaluate the efficacy of dutasteride 0.5 mg in PCa prevention among men with isolated HGPIN on biopsy. METHODS: This prospective, randomized, phase III, open-label 3-year trial assessed dutasteride versus active surveillance in patients with HGPIN. Patients were randomized to dutasteride 0...
September 19, 2016: World Journal of Urology
Josephina G Kuiper, Irene D Bezemer, Maurice T Driessen, Averyan Vasylyev, Claus G Roehrborn, Fernie J A Penning-van Beest, Ron M C Herings
BACKGROUND: Previous studies have suggested a greater benefit for various outcomes in men diagnosed with benign prostatic hyperplasia (BPH) who are treated with dutasteride than for men treated with finasteride. This study investigates whether the rates of BPH-related prostate surgery and acute urinary retention (AUR) differ between dutasteride and finasteride users in the Netherlands. METHODS: From the PHARMO Database Network, men aged ≥50 years with a dispensing of dutasteride or finasteride with or without concomitant alpha-blocker treatment between March 1, 2003 and December 31, 2011 were selected...
2016: BMC Urology
Paweł Paśko, Tomasz Rodacki, Renata Domagała-Rodacka, Danuta Owczarek
Benign prostatic hyperplasia (BPH) is the most common disease in elderly men. BPH symptoms include frequent urination, urgent tenesmus and urination at night, a weak and interrupted urine flow and a sense of incomplete emptying of the bladder. Alpha- 1 adrenergic receptor antagonists and 5 α-reductase inhibitors form the most important groups of medications employed in BPH. Appropriately managed BPH patients shall be subject to counselling on interactions between agents belonging to these groups, and on particular components of the food they have...
August 20, 2016: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
Sujit J S Shanshanwal, Rachita S Dhurat
BACKGROUND: Finasteride and dutasteride are inhibitors of the enzyme 5-alpha-reductase which inhibits the conversion of testosterone to dihydrotestosterone. Dutasteride inhibits both type I and type II 5-alpha-reductase while finasteride inhibits only the type II enzyme. As both isoenzymes are present in hair follicles, it is likely that dutasteride is more effective than finasteride. AIMS: To compare the efficacy, safety and tolerability of dutasteride and finasteride in men with androgenetic alopecia...
August 22, 2016: Indian Journal of Dermatology, Venereology and Leprology
Letteria Minutoli, Mariagrazia Rinaldi, Herbert Marini, Natasha Irrera, Giovanni Crea, Cesare Lorenzini, Domenico Puzzolo, Andrea Valenti, Antonina Pisani, Elena B Adamo, Domenica Altavilla, Francesco Squadrito, Antonio Micali
Benign prostatic hyperplasia (BPH) is a chronic condition common in older men that can result in bothersome lower urinary tract symptoms. The molecular mechanisms and networks underlying the development and the progression of the disease are still far from being fully understood. BPH results from smooth muscle cell and epithelial cell proliferation, primarily within the transition zone of the prostate. Apoptosis and inflammation play important roles in the control of cell growth and in the maintenance of tissue homeostasis...
2016: International Journal of Molecular Sciences
Masaki Shiota, Keijiro Kiyoshima, Akira Yokomizo, Ario Takeuchi, Eiji Kashiwagi, Takashi Dejima, Ryosuke Takahashi, Junichi Inokuchi, Katsunori Tatsugami, Masatoshi Eto
PURPOSE: To reveal whether intravesical recurrence is affected by an inhibition of androgen signaling among men with non-muscle invasive bladder cancer. MATERIALS AND METHODS: This study examined the intravesical recurrent rate among men treated with or without androgen-suppression therapy (AST) by androgen-deprivation therapy for prostate cancer or 5α-reductase inhibitor dutasteride for benign prostatic hyperplasia. RESULTS: This study included 228 men with AST (n = 32) or without AST (n = 196)...
August 6, 2016: Journal of Urology
Gwang Seong Choi, Joon Hyung Kim, Shin-Young Oh, Jung-Min Park, Ji-Soo Hong, Yil-Seob Lee, Won-Soo Lee
BACKGROUND: After the approval of dutastride for androgenic alopecia (AGA) in 2009, Korean authority required a post-marketing surveillance to obtain further data on its safety profile. OBJECTIVE: The objective was to monitor adverse events (AEs) of dutasteride 0.5 mg in Korean AGA male patients in a clinical practice environment. METHODS: Open label, multi-center, non-interventional observational study was done from July 2009 to July 2013...
August 2016: Annals of Dermatology
Luhao Liu, Shankun Zhao, Futian Li, Ermao Li, Ran Kang, Lianmin Luo, Jintai Luo, Shawpong Wan, Zhigang Zhao
INTRODUCTION: 5α-Reductase inhibitors (5ARIs) are widely used for the treatment of benign prostatic hyperplasia (BPH) and androgenetic alopecia (AGA). AIM: To review all the available data on the effect of 5ARIs on sexual function and assess whether 5ARIs increase the risk of sexual dysfunction. METHODS: A systematic search of the literature was conducted using the Medline, Embase, and Cochrane databases. The search was limited to articles published in English and up to October 2015...
September 2016: Journal of Sexual Medicine
Hamadeh Tarazi, Ekram Saleh, Raafat El-Awady
DNA-dependent protein kinase (DNA-PK) is a key enzyme in non-homologous DNA end joining (NHEJ) repair pathway. The targeted inhibition of such enzyme would furnish a valuable option for cancer treatment. In this study we report the development of validation of enzyme homology model, and the subsequent use of this model to perform docking-based virtual screening against a database of FDA-approved drugs. The nominated highest ranking hits (Praziquantel and Dutasteride) were subjected to biological investigation...
July 28, 2016: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
C J Corbin, E L Legacki, B A Ball, K E Scoggin, S D Stanley, A J Conley
The 5α-reductase enzymes play an important role during male sexual differentiation, and in pregnant females, especially equine species where maintenance relies on 5α-reduced progesterone, 5α-dihydroprogesterone (DHP). Epididymis expresses 5α-reductases but was not studied elaborately in horses. Epididymis from younger and older postpubertal stallions was divided into caput, corpus and cauda and examined for 5α-reductase activity and expression of type 1 and 2 isoforms by quantitative real-time polymerase chain reaction (qPCR)...
October 2016: Journal of Endocrinology
L E Fanton, C G Macedo, K E Torres-Chávez, L Fischer, C H Tambeli
BACKGROUND: Testosterone protects male rats from Temporomandibular Joint (TMJ) pain. This study investigated whether this protective effect is mediated by an organizational action of testosterone during nervous system development, by central estrogen and androgen receptors and by the 5α-reduced metabolite of testosterone, dihydrotestosterone. METHODS: A pharmacological approach was used to assess the ability of the androgen receptor antagonist flutamide, the estrogen receptor antagonist ICI 182780 and the 5-α reductase inhibitor dutasteride to block the protective effect of testosterone, evaluated through the behavioral response induced by a TMJ injection of 0...
July 23, 2016: Pharmacology, Biochemistry, and Behavior
Emeka I Udeh, Chimaobi G Ofoha, David A Adewole, Ikenna I Nnabugwu
BACKGROUND: The number of Nigerian men presenting with benign prostatic hyperplasia is on the rise because of increase awareness about the ailment. With the renewed effort by the national health insurance scheme to cover the informal sector, it becomes imperative to determine the cost implication for managing Benign Prostatic Hyperplasia (BPH) and the cost effective drug combination to be adopted. The objective of this study is to estimate cost effective analysis (CEA) of fixed -dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy from the health service provider perspective design...
2016: BMC Cancer
Martin C Michel
No abstract text is available yet for this article.
September 2016: Clinical Drug Investigation
Michael Fossler, John Zhu, Claus Roehrborn, Paul McAleese, Michael Manyak
BACKGROUND AND OBJECTIVES: Dutasteride is currently marketed by GlaxoSmithKline (GSK), either as monotherapy or as a fixed-dose combination with tamsulosin. As part of the project to develop the fixed-dose combination product, alternative formulations of dutasteride were prepared by GSK, and their pharmacokinetic properties were investigated. METHODS: Two single-centre, open-label, active-comparator, randomised, three-period crossover studies were performed. The first study evaluated the relative bioavailability of dutasteride 0...
September 2016: Clinical Drug Investigation
Claus G Roehrborn, Igor Oyarzabal Perez, Erik P M Roos, Nicolae Calomfirescu, Betsy Brotherton, Juan Manuel Palacios, Averyan Vasylyev, Michael J Manyak
PURPOSE: To investigate (in a post hoc analysis of the 2-year CONDUCT study) the characteristics and clinical outcomes of men with moderately symptomatic benign prostatic hyperplasia (BPH) at risk of progression who benefitted from lifestyle changes alone. METHODS: Patients were given lifestyle advice and randomized to a fixed-dose combination (FDC) of dutasteride and tamsulosin or watchful waiting (WW) and followed for 24 months. Patients in the WW group were escalated to tamsulosin if any follow-up International Prostate Symptom Score (IPSS) was equal or greater than the baseline value...
June 22, 2016: World Journal of Urology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"